BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 35582386)

  • 1. Notch signaling in female cancers: a multifaceted node to overcome drug resistance.
    Giuli MV; Mancusi A; Giuliani E; Screpanti I; Checquolo S
    Cancer Drug Resist; 2021; 4(4):805-836. PubMed ID: 35582386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer.
    Akbarzadeh M; Akbarzadeh S; Majidinia M
    Pathol Res Pract; 2020 Nov; 216(11):153158. PubMed ID: 32829107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells.
    Bao B; Wang Z; Ali S; Kong D; Li Y; Ahmad A; Banerjee S; Azmi AS; Miele L; Sarkar FH
    Cancer Lett; 2011 Aug; 307(1):26-36. PubMed ID: 21463919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
    BeLow M; Osipo C
    Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanism-based computational model to capture the interconnections among epithelial-mesenchymal transition, cancer stem cells and Notch-Jagged signaling.
    Bocci F; Jolly MK; George JT; Levine H; Onuchic JN
    Oncotarget; 2018 Jul; 9(52):29906-29920. PubMed ID: 30042822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistance.
    D'Amico M; De Amicis F
    Cancer Drug Resist; 2022; 5(4):939-953. PubMed ID: 36627893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
    Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
    J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells.
    Espinoza I; Miele L
    Cancer Lett; 2013 Nov; 341(1):41-5. PubMed ID: 23973264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
    Wang L; Dai G; Yang J; Wu W; Zhang W
    Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of EMT by Notch signaling pathway in tumor progression.
    Li Y; Ma J; Qian X; Wu Q; Xia J; Miele L; Sarkar FH; Wang Z
    Curr Cancer Drug Targets; 2013 Nov; 13(9):957-62. PubMed ID: 24168187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
    Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
    Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.
    Kang J; Kim E; Kim W; Seong KM; Youn H; Kim JW; Kim J; Youn B
    J Biol Chem; 2013 Sep; 288(38):27343-27357. PubMed ID: 23902763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-establishing Apoptosis Competence in Bone Associated Cancers via Communicative Reprogramming Induced Through Notch Signaling Inhibition.
    Colombo M; Platonova N; Giannandrea D; Palano MT; Basile A; Chiaramonte R
    Front Pharmacol; 2019; 10():145. PubMed ID: 30873026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch Signaling Pathway and Endocrine Resistance in Breast Cancer.
    Bai JW; Wei M; Li JW; Zhang GJ
    Front Pharmacol; 2020; 11():924. PubMed ID: 32636747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
    Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
    Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.
    Yuan X; Wu H; Han N; Xu H; Chu Q; Yu S; Chen Y; Wu K
    J Hematol Oncol; 2014 Dec; 7():87. PubMed ID: 25477004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMT.
    De Francesco EM; Maggiolini M; Musti AM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29996493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells.
    Zhang L; Sha J; Yang G; Huang X; Bo J; Huang Y
    Cell Cycle; 2017 May; 16(10):999-1007. PubMed ID: 28388267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.